Medicines Co
MDCO
MDCO was delisted on the 3rd of January, 2020.
202 hedge funds and large institutions have $2.61B invested in Medicines Co in 2017 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 83 increasing their positions, 63 reducing their positions, and 25 closing their positions.
48% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 25
32% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 63
6% more funds holding
Funds holding: 190 → 202 (+12)
12% less call options, than puts
Call options by funds: $40.3M | Put options by funds: $45.6M
23% less capital invested
Capital invested by funds: $3.37B → $2.61B (-$767M)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$49.3M |
| 2 |
GC
Greenlight Capital
New York
|
+$30.8M |
| 3 |
TBC
Three Bays Capital
Boston,
Massachusetts
|
+$30.2M |
| 4 |
JP Morgan Chase
New York
|
+$29.9M |
| 5 |
SPC
Slate Path Capital
New York
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$63.9M |
| 2 |
AH
Aviva Holdings
New Providence,
Bahamas
|
-$23.4M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$15.8M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$13.1M |
| 5 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
-$10.1M |
MDCO Hedge Fund Activity: Q4 2017 in Review
202 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Medicines Co (MDCO) for Q4 2017, worth a combined $2.61B — down 23% from $3.37B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MDCO positions and 25 closed out — a net gain of 12 holders — while 83 added to existing stakes and 63 trimmed.
The largest buyer was Camber Capital Management, opening a new position worth an estimated $49.3M. The largest seller was Goldman Sachs, cutting an estimated $63.9M.
- 202 institutional investors held Medicines Co (MDCO) as of Q4 2017, up from 190 in Q3 2017.
- Funds reported $2.61B of Medicines Co stock for Q4 2017, down 23% quarter-over-quarter.
- 37 funds opened new Medicines Co positions in Q4 2017 and 25 closed out, a net change of +12 holders.
- The largest Medicines Co buyer in Q4 2017 was Camber Capital Management, an estimated $49.3M added.
- The largest Medicines Co seller in Q4 2017 was Goldman Sachs, an estimated $63.9M sold.
Based on aggregated 13F filings for Q4 2017.